- Home
- ARVN vs GBLI Comparison
ARVN vs GBLI Comparison
Compare ARVN & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- GBLI
- Stock Information
- Founded
- ARVN 2015
- GBLI 2016
- Country
- ARVN United States
- GBLI United States
- Employees
- ARVN N/A
- GBLI N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- GBLI Property-Casualty Insurers
- Sector
- ARVN Health Care
- GBLI Finance
- Exchange
- ARVN Nasdaq
- GBLI Nasdaq
- Market Cap
- ARVN 456.2M
- GBLI 443.7M
- IPO Year
- ARVN 2018
- GBLI 2003
- Fundamental
- Price
- ARVN $7.80
- GBLI $31.97
- Analyst Decision
- ARVN Buy
- GBLI
- Analyst Count
- ARVN 21
- GBLI 0
- Target Price
- ARVN $20.53
- GBLI N/A
- AVG Volume (30 Days)
- ARVN 2.2M
- GBLI 1.2K
- Earning Date
- ARVN 07-29-2025
- GBLI 08-06-2025
- Dividend Yield
- ARVN N/A
- GBLI 4.48%
- EPS Growth
- ARVN N/A
- GBLI N/A
- EPS
- ARVN N/A
- GBLI 1.99
- Revenue
- ARVN $426,900,000.00
- GBLI $437,447,000.00
- Revenue This Year
- ARVN $4.26
- GBLI $7.67
- Revenue Next Year
- ARVN N/A
- GBLI $7.93
- P/E Ratio
- ARVN N/A
- GBLI $15.70
- Revenue Growth
- ARVN 498.74
- GBLI N/A
- 52 Week Low
- ARVN $5.90
- GBLI $26.94
- 52 Week High
- ARVN $34.11
- GBLI $37.00
- Technical
- Relative Strength Index (RSI)
- ARVN 58.03
- GBLI 54.55
- Support Level
- ARVN $7.09
- GBLI $30.36
- Resistance Level
- ARVN $7.85
- GBLI $32.58
- Average True Range (ATR)
- ARVN 0.40
- GBLI 0.43
- MACD
- ARVN 0.06
- GBLI 0.03
- Stochastic Oscillator
- ARVN 71.43
- GBLI 61.94
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.